Age Ups Risk for Acute Dacryocystitis in Blocked Tear Ducts
TOPLINE:
Acute dacryocystitis (AD) is common in women and becomes increasingly likely with age, particularly in individuals with primary acquired obstruction of the tear duct. To prevent this condition, clinicians may recommend surgery to create a new drainage pathway for tears in individuals aged 70 years or older who present symptoms such as excessive tearing or cysts filled with mucus in the eye.
METHODOLOGY:
Researchers conducted a retrospective observational study to determine the risk factors for AD in adults with or without primary acquired obstruction of the tear duct.
They analyzed 106 patients (mean age, 64.9 years; 81% women) diagnosed with AD between January 2000 and February 2020, considering only the first attack in case of recurrent episodes; those with congenital or secondary acquired obstruction of the tear duct were excluded.
AD was diagnosed when a patient suddenly developed swelling, redness, or pain in the inner corner of the eye, with or without a history of excessive tearing, an obstruction of the tear duct, or the presence of a cyst in the tear drainage system.
Patients were classified as having primary acquired obstruction of the tear duct if flushing the affected side with saline (before the onset of AD or after the infection calmed) showed a blockage.
Monthly averages of data on temperature, humidity, pressure, and amount of precipitation were collected from the Royal Meteorological Institute of Belgium over the entire duration of the study.
TAKEAWAY:
Half of the patients had a blockage in the tear duct, 20% had no blockage, and the rest could not be classified because data on flushing were missing or incomplete.
The incidence of AD rose significantly with age, with the risk increasing by 15.8% for every 5-year increase in age (exponentiated coefficient [Exp{B}], 1.158; P = .008).
In patients with a blockage of the tear duct, the risk rose by 22.1% for every 5-year increase in age (Exp[B], 1.221; P = .002); however, no association was observed between increased age and the risk for AD in patients with an open tear passage.
The incidence of AD was not statistically linked to any changes in the abovementioned weather conditions during the 14 days prior to infection onset.
IN PRACTICE:
The elevated risk for AD in older women with primary acquired nasolacrimal duct obstruction suggests the threshold to perform dacryocystorhinostomy should be lower for these patients, the researchers wrote. They proposed age 70 years as when clinicians should consider preventive dacryocystorhinostomy in patients with symptoms of primary acquired nasolacrimal duct obstruction, such as epiphora or mucocele.
SOURCE:
This study was led by Amber Demeuleneere of the Department of Ophthalmology at the University Hospitals Leuven, Leuven, Belgium. It was published online on June 18, 2025, in British Journal of Ophthalmology.
LIMITATIONS:
Mostly patients with severe AD were seen at the referral center. Those with blockage of the tear duct were not followed up over time. The use of weather averages on a monthly basis may have masked the effects of shorter durations of weather phenomena.
DISCLOSURES:
No grant support was received for this study. No relevant conflicts of interest were disclosed.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
44 minutes ago
- Medscape
Shifting the Narrative in Women's Health
Petra Simic, PhD AMSTERDAM, the Netherlands — When it comes to women's health, many people still think of 'breasts, uteruses, and hormones,' Petra Simic, PhD, a medical director at Bupa Health Clinics, said at HLTH Europe 2025 conference. But as clinicians, investors, and advocates made clear at the gathering, it is vastly more than that. The tide is slowly changing, fueled by data, technology, and a growing chorus of women's voices. Yet from diagnostics and research to clinical training and policy, systemic gaps remain. Acknowledging and actively closing these gaps is not just a matter of equality, it's a step toward better health outcomes for everyone, Anna Coates, PhD, a senior gender technical lead at the World Health Organization (WHO), told Medscape Medical News . Here Are Some Numbers The statistics around women's health remain shockingly grim, and their repetition might be a necessary reminder of the scale of the problem. Here are some numbers reported at the conference: Although women live longer than men, they spend 25% of their lives in greater illness and disability than men, which equates to an average of 9 years of poor health. Women are seven times more likely to be discriminated against by a healthcare provider. A woman is three times more likely than a man to be dismissed during a doctor's consultation. For the same disease, it can take a woman four times longer to receive a diagnosis. It takes an average of 6-10 years to diagnose a condition like endometriosis. A woman having a heart attack is seven times more likely to be dismissed and misdiagnosed in the emergency room and twice as likely to die as a result. While women constitute 70% of patients with chronic pain, 80% of pain medication research is conducted on men or male animals. Geography and income drastically alter outcomes. A woman diagnosed with breast cancer in a high-income country like Denmark has a 85%-90% 5-year survival rate. In India, that drops to around 60%, and in Nigeria, it is < 50%. In the US, a woman is now twice as likely to die in childbirth as her own mother was. Only 4% of venture capital investment in healthcare is directed toward women's health. Kristen Cerf Kristen Cerf, president and CEO at Blue Shield of California Promise Health Plan (PHP), pointed out that 'these statistics — every single one of them — worsen when talking about women of color.' These issues result in 75 million years of life lost due to poor health or early death annually. Closing the women's health gap could inject $1 trillion into the global economy by 2040. A Societal Problem Reflected in Healthcare These disparities are not solely a healthcare problem. Coates said that healthcare systems reflect broader society. 'If women are not generally valued, then we're going to see that replicated in the health system.' This isn't an external problem for medicine to point to, but rather one that it is an integral part of, she said. 'It's a societal problem, and you are part of that big society problem. So if the health system doesn't change, it's not playing its own role in that bigger societal change.' Moz Siddiqui 'It is a system's failure because mostly men have created that system," said Moz Siddiqui, a senior gender technical lead at the WHO Foundation. This systemic failure requires systemic stimuli to change. 'Systems don't change unless there are external stimuli,' said Cerf. But while moral arguments persist, many panelists agreed that financial and economic arguments are often more potent drivers. 'If the clinical and the patient perspective doesn't move governments, certainly the economics should move governments,' argued Tisha Boatman, who is responsible for external affairs and healthcare access at Siemens Healthineers. When the cost of misdiagnosis, lost productivity, and delayed treatment is quantified, the imperative to invest in women's health becomes undeniable, she said. Sleep: The Overlooked Pillar of Women's Health Tisha Boatman 'Sleep is really a core pillar of health, and it's just as important as nutrition, exercise, and stress resilience,' said Jennifer Kanady, PhD, director of sleep health technology at Samsung Electronics. Yet it is often the first thing to be sacrificed and the last to be addressed in clinical settings. Poor sleep is linked to increased risks for diabetes, heart disease, and dementia, and its patterns change significantly across a woman's life, influenced by menstrual cycles, pregnancy, and menopause. Insomnia, for example, might increase during pregnancy or the menopausal transition, but the causes and treatments might differ significantly depending on which of those phases a woman is in. This is where the diagnostic challenge becomes critical. A woman in perimenopause may visit her doctor complaining of fatigue and poor sleep. 'It might be diagnosed as insomnia, and the pattern is completely different,' said Ines Ramos Barreiras, EMEA regional medical advisor at Bayer. The root cause isn't a primary sleep disorder but a hormonal shift, meaning that a standard prescription for insomnia won't target the problem at its source. 'It's not only a problem of sleep, but how sleep is impacted,' she said. 'In menopause, women can go to sleep, but sleep is not as restoring as it needs to be.' Not a Smaller Man's Heart Cardiovascular disease is another space where a knowledge and awareness gap persists, both in the public domain and among healthcare practitioners. The public may not know the risks — Simic noted that a woman aged 45-65 years is 17 times more likely to die of cardiovascular disease than breast cancer — but the more critical gap is often with clinicians. 'We should stop treating the women's heart as a variation of the male heart,' said Michiel Winter, MD, a cardiologist at the Amsterdam University Medical Center who specializes in digital health. 'There's a very distinct difference. Risk factors like hypertension are much more harmful in women than in men, and it also means that they get different heart diseases, and that means different diagnostics and different therapy.' Even as technology advances, these old biases are being coded into new systems. 'Most algorithms are made for more male-specific cardiovascular disease,' Winter noted. For example, because the ST elevation in a female myocardial infarction is often less pronounced, 'the AI [artificial intelligence] algorithm picks up male STEMI (ST-elevation myocardial infarction) much more easily than it does for female.' Similarly, algorithms for interpreting ultrasounds are often better at identifying systolic heart failure (more common in men) than diastolic heart failure (more common in women). The Inevitable Transition Jocalyn Clark For too long, the narrative around menopause has been one of cessation and decline — a silent, private struggle marking the end of a woman's reproductive value. However, panelists at the HLTH Europe 2025 conference made clear that the story is being rewritten forcefully. What was once a taboo topic is now a 'menopause boom,' a global conversation fueled by a new generation of women demanding better information, care, and visibility, said Jocalyn Clark, the international editor at the British Medical Journal . 'When I came out of medical school, women disappeared from view of the health service at the age of 50 because they were postreproductive,' said Dame Lesley Regan, MD, a professor of obstetrics and gynecology at Imperial College London, London, England, and England's first Women's Health Ambassador. This perspective is dangerously outdated. With increasing lifespans, many women will now spend more of their lives postmenopausal than reproductive, she said. Dame Lesley Regan, MD The health risks that accelerate after menopause, such as cardiovascular disease and osteoporosis, are often overlooked in clinical consultations, often because healthcare professionals lack comprehensive menopause training, Regan said. In the UK, for example, general practitioners are no longer required to complete mandatory training in obstetrics and gynecology. Regan proposed that every healthcare professional — from orthopedic surgeons to cardiologists — should ask their female patients a simple question: 'Do you still have periods?' This, she argued, is a simple but important step to identifying women in the menopausal transition and ensuring their holistic health is considered. A New Narrative Bayo Curry-Winchell, MD The challenges are systemic, rooted in societal norms, and reflected in every corner of the healthcare industry. However, the collaboration between innovators, the commitment from advocates, and the increasing demand from patients are creating momentum, said Bayo Curry-Winchell, MD, a general practitioner in Reno, Nevada, and content creator. The solution lies in changing the narrative, she said. It requires normalizing conversations about menstruation, menopause, and every aspect of women's health. It means designing systems, products, and policies with women at the center. Most importantly, it involves listening to women from diverse backgrounds. As Ramos Barreiras said, there is a cultural expectation for women to be quiet. 'We don't complain. We were taught to be strong and to endure. And this is the shift we are seeking: to empower women to be vocal about what we want and the quality of life we deserve.' Simic is a medical director at Bupa Health Clinics; Cerf is the president and CEO at Blue Shield of California PHP; Boatman is responsible for external affairs and healthcare access at Siemens Healthineers; Kanady is the director of sleep health technology at Samsung Electronics; Ramos Barreiras is a EMEA Regional Medical Advisor at Bayer.
Yahoo
an hour ago
- Yahoo
The mystery of Mercury's missing meteorites – and how we may have finally found some
Most meteorites that have reached Earth come from the asteroid belt between Mars and Jupiter. But we have 1,000 or so meteorites that come from the Moon and Mars. This is probably a result of asteroids hitting their surfaces and ejecting material towards our planet. It should also be physically possible for such debris to reach the Earth from Mercury, another nearby rocky body. But so far, none have been confirmed to come from there – presenting a longstanding mystery. A new study my colleagues and I conducted has discovered two meteorites that could have a Mercurian origin. If confirmed, they would offer a rare window into Mercury's formation and evolution, potentially reshaping our understanding of the planet nearest the Sun. Because Mercury is so close to the Sun, any space mission to retrieve a sample from there would be complex and costly. A naturally delivered fragment, therefore, may be the only practical way to study its surface directly – making such a discovery scientifically invaluable. Get your news from actual experts, straight to your inbox. Sign up to our daily newsletter to receive all The Conversation UK's latest coverage of news and research, from politics and business to the arts and sciences. Observations from Nasa's Messenger mission have inferred the surface composition of Mercury. This suggests the presence of minerals known as such as sodium-rich plagioclase (such as albite), iron-poor pyroxene (for example enstatite), iron-poor olivine (such as forsterite) and sulfide minerals such as oldhamite. The meteorite Northwest Africa (NWA) 7325 was initially proposed as a possible fragment of Mercury. However, its mineralogy includes chromium-rich pyroxene containing approximately 1% iron. This poorly matches Mercury's estimated surface composition. As a result of this, and other factors, this link has been challenged. Aubrite meteorites have also been proposed as potential Mercurian fragments. Recent modelling of their formation suggests an origin from a large planetary body approximately 5,000km in diameter (similar to Mercury), potentially supporting this hypothesis. Although aubrites do not exhibit chemical or spectral (the study of how light is broken up by wavelength) similarities with Mercury's surface, it has been hypothesised that they may derive from the planet's shallow mantle (the layer beneath the surface). Despite ongoing research, the existence of a definitive meteorite from Mercury remains unproven. Our latest study investigated the properties of two unusual meteorites, Ksar Ghilane 022 and Northwest Africa 15915. We found that the two samples appear to be related, probably originating from the same parent body. Their mineralogy and surface composition also exhibit intriguing similarities to Mercury's crust. So this has prompted us to speculate about a possible Mercurian origin. Both meteorites contain olivine and pyroxene, minor albitic plagioclase and oldhamite. Such features are consistent with predictions for Mercury's surface composition. Additionally, their oxygen compositions match those of aubrites. These shared characteristics make the samples compelling candidates for being Mercurian material. However, notable differences exist. Both meteorites contain only trace amounts of plagioclase, in contrast to Mercury's surface, which is estimated to contain over 37%. Furthermore, our study suggests that the age of the samples is about 4,528 million years old. This is significantly older than Mercury's oldest recognised surface units, which are predicted (based on crater counting) to be approximately 4,000 million years. If these meteorites do originate from Mercury, they may represent early material that is no longer preserved in the planet's current surface geology. To link any meteorite to a specific asteroid type, moon or planet is extremely challenging. For example, laboratory analysis of Apollo samples allowed meteorites found in desert collection expeditions to be matched with the lunar materials. Martian meteorites have been identified through similarities between the composition of gases trapped in the meteorites with measurements of the martian atmosphere by spacecraft. Until we visit Mercury and bring back material, it will be extremely difficult to assess a meteorite-planet link. The BepiColombo space mission, by the European and Japanese space agencies, is now in orbit around Mercury and is about to send back high-resolution data. This may help us determine the ultimate origin body for Ksar Ghilane 022 and Northwest Africa 15915. If meteorites from Mercury were discovered, they could help resolve a variety of long-standing scientific questions. For example, they could reveal the age and evolution of Mercury's crust, its mineralogical and geochemical composition and the nature of its gases. The origin of these samples is likely to remain a subject of continuing debate within the scientific community. Several presentations have already been scheduled for the upcoming Meteoritical Society Meeting 2025 in Australia. We look forward to future discussions that will further explore and refine our understanding of their potential origin. For now, all we can do is make educated guesses. What do you think? This article is republished from The Conversation under a Creative Commons license. Read the original article. Ben Rider-Stokes receives funding from the Science and Technology Facilities Council (STFC).
Yahoo
2 hours ago
- Yahoo
Some people are turning to nicotine gum and patches to treat long COVID brain fog
Some people with long COVID are turning to an unlikely remedy: nicotine gum and patches. Though typically used to quit smoking, nicotine is now being explored as a possible way to ease symptoms such as brain fog and fatigue. One such case, detailed in a recent article in Slate, describes a woman who found significant relief from debilitating brain fog after trying low-dose nicotine gum. Her experience, while anecdotal, aligns with findings from a small but interesting study from Germany. The study involved four participants suffering from symptoms related to long COVID. The researcher administered low-dose nicotine patches once daily and noticed marked improvements in the participants' symptoms. Tiredness, weakness, shortness of breath and trouble with exercise rapidly improved – by day six at the latest. For those who had lost their sense of taste or smell, it took longer, but these senses came back fully within 16 days. Although it's not possible to draw definitive conclusions on cause and effect from such a small study, the results could pave the way for larger studies. Get your news from actual experts, straight to your inbox. Sign up to our daily newsletter to receive all The Conversation UK's latest coverage of news and research, from politics and business to the arts and sciences. While some people slowly recover from COVID, others remain unwell for years, especially those who became sick before vaccines were available. Between 3% and 5% of people continue to experience symptoms months, and sometimes even years, after the initial infection. In the UK, long COVID affects around 2.8% of the population. Brain fog and other neurological symptoms of long COVID are thought to result from a combination of factors – including inflammation, reduced oxygen to the brain, vascular damage and disruption to the blood-brain barrier. Research continues as there is still a lot we don't know about this condition. The researcher in the German study thinks that long COVID symptoms, such as fatigue, brain fog and mood changes, might partly be due to problems with a brain chemical called acetylcholine, a neurotransmitter. This chemical is important for many functions in the body, including memory, attention and regulating mood. Normally, acetylcholine works by attaching to special 'docking sites' on cells called nicotinic acetylcholine receptors, which help send signals in the brain and nervous system. But the COVID virus may interfere with these receptors, either by blocking them or disrupting how they work. When this happens, the brain may not be able to send signals properly, which could contribute to the mental and physical symptoms seen in long COVID. So why would nicotine potentially be useful? Nicotine binds to the same receptors and might help restore normal signalling, but the idea that it displaces the virus directly is still speculative. Nicotine is available in different forms, such as patches, gum, lozenges and sprays. Using nicotine through the skin, for example, with a patch, keeps the amount in the blood steady without big spikes. Because of this, people in the study didn't seem to develop a dependence on it. Chewing nicotine gum or using a lozenge can cause spikes in nicotine levels, since the nicotine is absorbed gradually through the lining of the mouth. But unlike a patch, which delivers a steady dose, the user has more control over how much nicotine they take in when using gum or lozenges. There are mixed results on the effectiveness of nicotine on cognitive functions such as memory and concentration. But most studies agree that it can enhance attention. Larger studies are needed to gauge the effectiveness of nicotine specifically for long COVID symptoms. Despite its benefits, nicotine is not without risks. Even in gum or patch form, it can cause side-effects like nausea, dizziness, increased heart rate and higher blood pressure. Some of these stimulant effects on heart rate may be useful for people with long COVID symptoms such as exercise intolerance. But this needs to be closely monitored. Long-term use may also affect heart health. For non-smokers, the risk of developing a nicotine dependency is a serious concern. So are there any options to treat long COVID symptoms? There are some studies looking at guanfacine in combination with N-acetylcysteine, which have shown improvement in brain fog in small groups of people. There has been at least one clinical trial exploring nicotine for mild cognitive impairment in older adults, though not in the context of long COVID. Given that anecdotal reports and small studies continue to draw attention, it is likely that targeted trials are in development. The main recommendations by experts are to implement lifestyle measures. Slowly increasing exercise, having a healthy diet, avoiding alcohol, drugs and smoking, sleeping enough, practising mindfulness and doing things that stimulate the brain are all thought to help brain fog. For those grappling with long COVID or persistent brain fog, the idea of using nicotine patches or gum might be tempting. But experts caution against self-medicating with nicotine. The lack of standardised dosing and the potential for addiction and unknown long-term effects make it a risky experiment. While nicotine isn't a cure and may carry real risks, its potential to ease long COVID symptoms warrants careful study. For now, those battling brain fog should approach it with caution – and always under medical supervision. What's clear, though, is the urgent need for more research into safe, effective treatments for the lingering effects of COVID. This article is republished from The Conversation under a Creative Commons license. Read the original article. Dipa Kamdar does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.
